Search Results for "prepared"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for prepared. Results 11 to 20 of 47 total matches.
Idecabtagene Vicleucel (Abecma) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
is
an individualized cellular product prepared from the
patient’s own T cells, which are genetically modified ...
The FDA has approved idecabtagene vicleucel
(Abecma – BMS), a B-cell maturation antigen (BCMA)-directed genetically-modified cellular product, for
treatment of relapsed or refractory multiple myeloma in
adults who received ≥4 prior lines of therapy, including
a proteasome inhibitor, an immunomodulatory drug,
and an anti-CD38 monoclonal antibody. Abecma is
an individualized cellular product prepared from the
patient’s own T cells, which are genetically modified
to express chimeric antigen receptors (CAR) and
then infused back into the patient. Ciltacabtagene
autoleucel...
Varenicline Nasal Spray (Tyrvaya) for Dry Eye Disease
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021 (Issue 1639)
with ophthalmic preparations used for treatment of
dry eye disease are available.
ADVERSE EFFECTS — The most ...
Tyrvaya (Oyster Point), a nasal spray formulation
of the cholinergic agonist varenicline, has been
approved by the FDA for treatment of dry eye disease.
It is the first nasal spray to be approved in the US
for this indication. An oral formulation of varenicline
(Chantix, and generics) has been available for years
for smoking cessation.
A New Indication for Axicabtagene Ciloleucel (Yescarta) (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
prepared from the
patient's own T cells, which are genetically modified
to express chimeric antigen ...
The FDA recently approved axicabtagene ciloleucel
(Yescarta – Kite), a CD19-directed genetically
modified cellular product, for treatment of large B-cell
lymphoma that is refractory to first-line chemoimmunotherapy
or that relapses within 12 months
of first-line treatment. It was previously approved for
treatment of relapsed or refractory B-cell lymphoma
after ≥2 lines of systemic therapy and for treatment
of relapsed or refractory follicular lymphoma
after ≥2 lines of systemic therapy. Yescarta is an
individualized cellular product prepared from the
patient's own T cells,...
In Brief: Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023 (Issue 1679)
after ≥2 lines of systemic
therapy. Breyanzi is an individualized cellular
product prepared ...
The FDA has approved lisocabtagene maraleucel
(Breyanzi – BMS) for treatment of adults with large
B-cell lymphoma (LBCL), including diffuse large
B-cell lymphoma (DLBCL) not otherwise specified,
high-grade B-cell lymphoma, primary mediastinal
large B-cell lymphoma, or follicular lymphoma
grade 3B who have disease refractory to first-line
chemoimmunotherapy, relapsed within 12 months
of or after first-line chemoimmunotherapy, are not
eligible for hematopoietic stem cell transplantation
due to comorbidities or age, or have relapsed
or refractory disease after ≥2 lines of...
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e104-5 doi:10.58347/tml.2023.1679f | Show Introduction Hide Introduction
Ciltacabtagene Autoleucel (Carvykti) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
antibody. Carvykti is an individualized
cellular product prepared from the patient's own
T cells, which ...
The FDA has approved ciltacabtagene autoleucel
(Carvykti – Janssen), a B-cell maturation antigen
(BCMA)-directed genetically-modified cellular product,
for treatment of relapsed or refractory
multiple myeloma in adults who received ≥4 prior
lines of therapy, including a proteasome inhibitor,
an immunomodulatory drug, and an anti-CD38
monoclonal antibody. Carvykti is an individualized
cellular product prepared from the patient's own
T cells, which are genetically modified to express
chimeric antigen receptors (CAR) and then infused
back into the patient. Idecabtagene...
Vyalev — Foscarbidopa/Foslevodopa Subcutaneous Infusion for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jan 06, 2025 (Issue 1719)
vials containing 120 mg
of foscarbidopa and 2400 mg of foslevodopa.
Preparation for administration ...
Vyalev (Abbvie), a solution for continuous subcutaneous
infusion containing the prodrugs foscarbidopa
and foslevodopa, has been approved by the FDA
for treatment of motor fluctuations in adults with
advanced Parkinson's disease (PD). Vyalev is the first
subcutaneously administered product to become
available in the US for treatment of PD symptoms. Duopa,
a carbidopa/levodopa enteral suspension infused via a
nasojejunal tube or percutaneous gastrostomy, was
approved in for the same indication 2015.
Med Lett Drugs Ther. 2025 Jan 6;67(1719):7-8 doi:10.58347/tml.2025.1719c | Show Introduction Hide Introduction
An EUA for Casirivimab and Imdevimab for COVID-19
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
minutes before dose preparation.
The two antibodies are only authorized for
administration together ...
The FDA has issued an Emergency Use Authorization
(EUA) for Regeneron's investigational monoclonal
antibodies casirivimab and imdevimab (REGEN-COV)
to be administered together by IV infusion or SC
injection for treatment of mild to moderate COVID-19
in adults and pediatric patients (≥12 years old and
weigh ≥40 kg) who are at high risk of progressing to
severe COVID-19 and/or hospitalization.
Relyvrio for ALS
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
within 1 hour of preparation. The
suspension can be taken orally or via feeding tube.
The recommended ...
The FDA has approved Relyvrio (Amylyx), a fixed-dose
combination of sodium phenylbutyrate and
taurursodiol, for treatment of amyotrophic lateral
sclerosis (ALS). Sodium phenylbutyrate (Buphenyl,
and others) has been available by prescription
for years for treatment of urea cycle disorders.
Taurursodiol (tauroursodeoxycholic acid), a derivative
of ursodiol, is an over-the-counter bile acid
supplement claimed to have neuroprotective
benefits. Relyvrio is the third drug to be approved
in the US for treatment of ALS; riluzole (Rilutek, and
others) and edaravone (Radicava, Radicava...
Table: Correct Use of Inhalers for COPD (online only)
The Medical Letter on Drugs and Therapeutics • Sep 07, 2020 (Issue 1606)
Prepare the dose by sliding the lever next to the mouthpiece away
from you until it clicks
Exhale fully ...
View the Table: Correct Use of Inhalers for COPD
In Brief: Obecabtagene Autoleucel (Aucatzyl) - Another CAR-T Cell Immunotherapy for ALL (online only)
The Medical Letter on Drugs and Therapeutics • Dec 23, 2024 (Issue 1718)
is an individualized cellular product prepared from the patient’s own T cells, which are genetically modified ...
Obecabtagene autoleucel (Aucatzyl – Autolus), a
CD19-directed genetically modified autologous T cell
immunotherapy, has been approved by the FDA for
treatment of relapsed or refractory B-cell precursor
acute lymphoblastic leukemia (ALL) in adults. The
CAR T-cell immunotherapy products tisagenlecleucel
(Kymriah) and brexucabtagene auto-leucel (Tecartus)
were approved earlier for the same indication.
Med Lett Drugs Ther. 2024 Dec 23;66(1718):e208 doi:10.58347/tml.2024.1718f | Show Introduction Hide Introduction